3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
58
Rituximab
54
fludarabine
33
fludarabine phosphate
32
venetoclax
24
Filgrastim
22
Etoposide
18
Bendamustine Hydrochloride
18
Gemcitabine
17
Peripheral Blood Stem Cell Transplantation
15
Bortezomib
15
Melphalan
14
obinutuzumab
13
Lenalidomide
12
Dexamethasone
12
Cytarabine
12
Vincristine
11
Vorinostat
10
Tacrolimus
10
Azacitidine
10
pembrolizumab
9
Prednisone
9
Mycophenolic Acid
9
Doxorubicin
9
ibrutinib
8
copanlisib
8
Whole-Body Irradiation
8
Radiotherapy
8
Paclitaxel
8
Interleukin-2
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma, Non-Hodgkin
×
tenalisib
×
Clear all
NCT02017613
2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1
Completed
35 enrolled